DRW Securities’s Cytokinetics CYTK Stock Holding History

DRW Securities’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-26,900	Closed	-$1.89M	–	550
2024 Q1	$1.89M	Buy	+26,900	New	+$2.08M	0.05%	126

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DRW Securities's CYTK Position: Q3 2018 in Review

DRW Securities sold out of Cytokinetics (CYTK) in Q3 2018, closing a stake of 26,797 shares — an estimated $222K sold.

DRW Securities first reported a position in CYTK in Q3 2013 and held it in 5 quarters. The position peaked at $222K in Q2 2018. 122 funds tracked by Wall St. Rank hold CYTK as of Q3 2018.

DRW Securities reported no remaining Cytokinetics position as of Q3 2018 after selling out during the quarter.
DRW Securities sold 26,797 Cytokinetics shares in Q3 2018, an estimated $222K.
DRW Securities first reported a position in Cytokinetics in Q3 2013 and held it in 5 quarters.
DRW Securities's Cytokinetics position peaked at $222K in Q2 2018.
122 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2018.

Based on DRW Securities's 13F filing for Q3 2018, filed 14 Nov 2018.